He turned a fiddly, high-stakes moment in spine surgery into a business - and put a small Austin device company on shelves next to Medtronic.
The complication is common enough that spine surgeons have a name for it and a quiet dread of it: the dural tear. A slip during surgery opens the thin membrane around the spinal cord, and suddenly a routine case turns into a slow, delicate repair with real stakes. For decades the fix has depended on a surgeon's hands, patience, and a needle rotated by the wrist inside a cramped opening. Adam Azzara looked at that moment and saw something most people miss in medicine: a business.
Azzara is the CEO of DuraStat, an Austin device company built around a suturing tool that automates the fiddliest part of that repair. He did not invent it. Two spine surgeons, Greg Anderson and Mark Kurd, did. What Azzara did was arguably harder. He took a clever idea sitting in a handful of operating rooms and put it on the shelf in all 50 states.
Incidental durotomy - the technical term for that accidental tear - is one of the most common complications in spine surgery. Left poorly sealed, it can lead to a persistent leak of cerebrospinal fluid, which means longer recoveries and repeat interventions. The repair itself is unglamorous: stitch the membrane closed, cleanly, in an awkward space, without making things worse.
DuraStat's design idea is almost boringly simple, which is the point. Eliminate the wrist rotation. By pre-selecting needle placement and automating the suture passage, the device lets a surgeon approximate tissue faster and with less trauma. Fewer motions, fewer variables, a more reproducible result. It is the kind of subtraction that sounds obvious only after someone builds it.
Azzara did not arrive at DuraStat as a founder or a surgeon. He came in through the commercial door, as vice president of sales and marketing in 2020, and moved into the CEO seat in 2022. That path matters. Before he was setting strategy, he was in the field learning exactly how a device like this gets adopted - who signs off, what a hospital will pay, why a surgeon switches or does not.
His background runs back to San Diego State University, where he was involved in Students In Free Enterprise and the school's Small Business Consulting group. His own stated ambition, plainly, is to establish, operate and expand businesses that develop and commercialize new products. DuraStat is that sentence in practice.
1. Sell the boring thing that works. Simple, cost-effective, clinically accepted - in that order.
2. Get close to the customer before you lead. Field experience first, title second.
3. Stack partnerships. Each deal makes the next one easier to sign.
4. Name the finish line. "On shelf at every facility performing spine surgery."
The commercial story reads like a set of stairs. In April 2022, DuraStat closed a Series B of more than $5 million and relocated its headquarters to Austin. The company was already operating in 43 states and forecasting aggressive growth. In March 2023 came a Breakthrough Technology Agreement with Premier, the giant hospital purchasing network, which gave members pre-negotiated access to the product.
Then, in November 2024, the biggest step: an exclusive U.S. commercial partnership with Medtronic's Cranial & Spinal Technologies business. For a company of roughly 14 people, sharing distribution muscle with one of the largest medical device makers on earth is the kind of leverage that money alone cannot buy. By then, DuraStat had already moved more than 10,000 units across every state.
Azzara does not run DuraStat alone, and the names around him say a lot about where the company sits in the spine world. The chairman is Alex Lukianov, founder and former CEO of NuVasive, one of the defining companies in modern spine surgery. Kevin Foley, a widely known neurosurgeon, sits on the board. The inventors, Anderson and Kurd, anchor the surgeon advisory side. It is a small team wearing a lot of experience.
That mix - surgeon inventors, a spine-industry chairman, and a commercially minded CEO - is a clean division of labor. The surgeons make sure the product earns trust in the operating room. Azzara makes sure it gets there.
The pitch Azzara keeps returning to is that DuraStat is not really one product. It is a suturing platform with many possible embodiments across surgical disciplines. The next chapters are already named: a second-generation DuraStat device and TissueStat, a minimally invasive fascial closure tool. Both are pointed at the same idea - the small, repeatable moments in surgery that eat time and invite error.
There is a certain discipline in how Azzara talks about all of it. No moonshot language, no reinventing medicine. Just a repeated insistence that the best products in surgery are the ones that are simple, cheap, and proven - and that a small company can go everywhere if it partners well. The vision he states out loud is unhedged: put DuraStat and TissueStat on the shelf at every facility performing spine surgery. It is a goal you can picture, which is exactly why a team can chase it.
Somewhere in an operating room this week, a surgeon will hit that same small tear that has slowed cases for a generation. If Azzara has his way, the fix will be sitting on the shelf, ready, and the case will barely lose a beat. That is the whole ambition, and it is a bigger one than it sounds.